Tier 2 — strong

Beyond Nano-Delivery: Synerjet-Assisted Transdermal Delivery of Nano-Formulated Nicotinamide Mononucleotide (Nano-NMN) for Comprehensive Skin Rejuvenation

Wonkyu Hong, Jaewoo Kim, Seongmin Noh, Joonho Shim, Seok-Kwang Park, Mihwa Kim
Cosmetics 2026 13(4):172

Bibliography

DOI
10.3390/cosmetics13040172
Funding
The final peer-reviewed disclosure states that the research was funded by DEFY NUMBER Co., Ltd. The peer-review record notes that an earlier draft incorrectly listed Hironic Co., Ltd. as a funder and was corrected during review.
Competing interests
Seok-Kwang Park and Mihwa Kim were employed by Hironic Co., Ltd. when the manuscript was written; the authors state the experimental phase and data collection were completed before that employment and that Hironic did not fund the study. The remaining authors declared no conflicts. DEFY NUMBER Co., Ltd. funded the research.

Study snapshot

DesignFour-week prospective split-face controlled human study. Right facial side received 10% nano-NMN plus Synerjet device-assisted delivery; left side received topical 10% nano-NMN alone.
ModelHealthy Korean women with visible facial skin-aging signs including wrinkles, enlarged pores, reduced elasticity and hyperpigmentation.
Sample21 participants enrolled; one participant was withdrawn at week 4 for a protocol violation. Mean age 61.76 ± 8.2 years; reported range 47–73 years.
InterventionTest side: 10% nano-NMN ampoule with cold-plasma preparation, electroporation and Synerjet microjet treatment once weekly for 4 weeks. Control side: topical 10% nano-NMN ampoule twice daily for 4 weeks.
Duration4 weeks
EndpointsPeriorbital wrinkle depth; Nasolabial wrinkle depth; Pore volume; Skin elasticity; Melanin intensity and pigmentation area; Skin hydration at multiple depths; Participant-reported satisfaction; Adverse effects/tolerability

What the study showed, in plain terms

This 2026 peer-reviewed split-face study tested whether a professional device system could deliver a 10% nano-NMN ampoule more effectively than applying the same nano-NMN topically. One side of each participant's face received weekly cold-plasma/electroporation/microjet-assisted treatment, while the other side used topical nano-NMN twice daily.

The device-assisted side improved measured wrinkles, pores, elasticity, pigmentation and hydration more than topical nano-NMN alone over four weeks.

The result does not show that oral NMN supplements improve skin, and it does not isolate the effect of NMN itself because both sides received NMN and the test side added several delivery technologies. It is evidence for a specific topical combination procedure.

Key findings

  • Device-assisted nano-NMN produced significantly greater improvement than topical nano-NMN alone across multiple measured facial skin parameters over four weeks.
  • The test side used a combined cold-plasma, electroporation and microjet delivery system, so the study cannot attribute the additional effect to NMN alone.
  • Both facial sides received 10% nano-NMN, which means the trial did not include a vehicle-only or no-NMN control.
  • The study reported high compliance and no participant-reported intolerable pain or major adverse effects requiring analgesia or sedation.
  • The trial provides human topical/procedural evidence but no evidence that swallowing NMN improves wrinkles, elasticity or pigmentation.

What this study can and cannot tell us

The trial was small, short and used a fixed right-face test/left-face control assignment rather than randomized side allocation. Split-face designs reduce between-person variability but can still be vulnerable to side-specific bias.

The experimental condition combined three device technologies with nano-NMN, while the control received topical nano-NMN alone. The design therefore tests the added value of the delivery procedure, not NMN versus placebo and not oral NMN supplementation.

There was no vehicle-only control, so the study cannot establish how much of either side's change was caused by NMN itself versus skincare routine, repeated application or other study effects.

The research was funded by DEFY NUMBER Co., Ltd., and two authors were employed by Hironic Co., Ltd., the device manufacturer, when the manuscript was written. These relationships were disclosed and clarified during peer review.

Citation network

Articles citing this research paper

3 articles

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology